-
Something wrong with this record ?
Platinum(II) oxalato complexes with adenine-based carrier ligands showing significant in vitro antitumor activity
P. Starha, Z. Trávnícek, I. Popa,
Language English Country United States
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Adenine chemistry MeSH
- Cisplatin pharmacology MeSH
- Crystallography, X-Ray MeSH
- Humans MeSH
- Magnetic Resonance Spectroscopy MeSH
- Cell Line, Tumor MeSH
- Organoplatinum Compounds chemical synthesis chemistry pharmacology MeSH
- Antineoplastic Agents chemical synthesis chemistry pharmacology MeSH
- Cell Survival drug effects MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
[Pt(L)(2)(ox)] (1), [Pt(2-OMeL)(2)(ox)] (2), [Pt(3-OMeL)(2)(ox)] (3), [Pt(2,3-diOMeL)(2)(ox)] (4), [Pt(2,4-diOMeL)(2)(ox)] (5), [Pt(3,4-diOMeL)(2)(ox)] (6) and [Pt(3,5-diOMeL)(2)(ox)].4H(2)O (7) platinum(II) oxalato (ox) complexes were synthesized using the reaction of potassium bis(oxalato)platinate(II) dihydrate with 2-chloro-N6-(benzyl)-9-isopropyladenine or its benzyl-substituted analogues (nL). The complexes 1-7, which represent the first platinum(II) oxalato complexes involving adenine-based ligands, were fully characterized by various physical methods including multinuclear and two dimensional NMR spectroscopy. A single-crystal X-ray analysis of [Pt(2,4-diOMeL)(2)(ox)].2DMF (5.2DMF; DMF=N,N'-dimethylformamide), proved the slightly distorted square-planar geometry in the vicinity of the Pt(II) ion with one bidentate-coordinated oxalate dianion and two adenine derivatives (nL) coordinated to the Pt(II) centre through the N7 atom of an adenine moiety, thereby giving a PtN(2)O(2) donor set. In vitro cytotoxicity of the prepared complexes was tested by an MTT assay against osteosarcoma (HOS) and breast adenocarcinoma (MCF7) human cancer cell lines. The best results were achieved for the complexes 2 and 5 in the case of both cell lines, whose IC(50) values equalled 3.6+/-1.0, and 4.3+/-2.1microM (for 2), and 5.4+/-3.8, and 3.6+/-2.1microM (for 5), respectively. The IC(50) equals 9.2+/-1.5microM against MCF7 cells in the case of 1. The in vitro cytotoxicity of the mentioned complexes significantly exceeded commercially used platinum-based anticancer drugs cisplatin (34.2+/-6.4microM and 19.6+/-4.3microM) and oxaliplatin (>50.0microM for both cancer cell lines).
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc12025859
- 003
- CZ-PrNML
- 005
- 20121207125651.0
- 007
- ta
- 008
- 120817e20100303xxu f 000 0#eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.jinorgbio.2010.02.005 $2 doi
- 035 __
- $a (PubMed)20304500
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Starha, Pavel $u Department of Inorganic Chemistry, Faculty of Science, Palacký University, Trída 17. listopadu 12, CZ-771 46 Olomouc, Czech Republic.
- 245 10
- $a Platinum(II) oxalato complexes with adenine-based carrier ligands showing significant in vitro antitumor activity / $c P. Starha, Z. Trávnícek, I. Popa,
- 520 9_
- $a [Pt(L)(2)(ox)] (1), [Pt(2-OMeL)(2)(ox)] (2), [Pt(3-OMeL)(2)(ox)] (3), [Pt(2,3-diOMeL)(2)(ox)] (4), [Pt(2,4-diOMeL)(2)(ox)] (5), [Pt(3,4-diOMeL)(2)(ox)] (6) and [Pt(3,5-diOMeL)(2)(ox)].4H(2)O (7) platinum(II) oxalato (ox) complexes were synthesized using the reaction of potassium bis(oxalato)platinate(II) dihydrate with 2-chloro-N6-(benzyl)-9-isopropyladenine or its benzyl-substituted analogues (nL). The complexes 1-7, which represent the first platinum(II) oxalato complexes involving adenine-based ligands, were fully characterized by various physical methods including multinuclear and two dimensional NMR spectroscopy. A single-crystal X-ray analysis of [Pt(2,4-diOMeL)(2)(ox)].2DMF (5.2DMF; DMF=N,N'-dimethylformamide), proved the slightly distorted square-planar geometry in the vicinity of the Pt(II) ion with one bidentate-coordinated oxalate dianion and two adenine derivatives (nL) coordinated to the Pt(II) centre through the N7 atom of an adenine moiety, thereby giving a PtN(2)O(2) donor set. In vitro cytotoxicity of the prepared complexes was tested by an MTT assay against osteosarcoma (HOS) and breast adenocarcinoma (MCF7) human cancer cell lines. The best results were achieved for the complexes 2 and 5 in the case of both cell lines, whose IC(50) values equalled 3.6+/-1.0, and 4.3+/-2.1microM (for 2), and 5.4+/-3.8, and 3.6+/-2.1microM (for 5), respectively. The IC(50) equals 9.2+/-1.5microM against MCF7 cells in the case of 1. The in vitro cytotoxicity of the mentioned complexes significantly exceeded commercially used platinum-based anticancer drugs cisplatin (34.2+/-6.4microM and 19.6+/-4.3microM) and oxaliplatin (>50.0microM for both cancer cell lines).
- 650 _2
- $a adenin $x chemie $7 D000225
- 650 _2
- $a protinádorové látky $x chemická syntéza $x chemie $x farmakologie $7 D000970
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a viabilita buněk $x účinky léků $7 D002470
- 650 _2
- $a cisplatina $x farmakologie $7 D002945
- 650 _2
- $a krystalografie rentgenová $7 D018360
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a magnetická rezonanční spektroskopie $7 D009682
- 650 _2
- $a organoplatinové sloučeniny $x chemická syntéza $x chemie $x farmakologie $7 D009944
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Trávnícek, Zdenek
- 700 1_
- $a Popa, Igor
- 773 0_
- $w MED00006646 $t Journal of inorganic biochemistry $x 1873-3344 $g Roč. 104, č. 6 (20100303), s. 639-47
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/20304500 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y m
- 990 __
- $a 20120817 $b ABA008
- 991 __
- $a 20121207125725 $b ABA008
- 999 __
- $a ok $b bmc $g 947901 $s 783205
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2010 $b 104 $c 6 $d 639-47 $e 20100303 $i 1873-3344 $m Journal of inorganic biochemistry $n J Inorg Biochem $x MED00006646
- LZP __
- $a Pubmed-20120817/10/03